Skip to content

Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease

Mapping Multidimensional Illness Trajectories of Patients With ESKD

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01530945
Enrollment
227
Registered
2012-02-10
Start date
2012-03-31
Completion date
2015-07-31
Last updated
2015-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Kidney Disease

Brief summary

Patients with end-stage kidney disease (ESKD) must manage not only the demands of dialysis and comorbid conditions but also associated symptoms and acute life-threatening events that contribute to functional limitations and increased risk of mortality. Yet little is known about the trajectories of quality of life dimensions in patients with ESKD when they experience acute life-threatening episodes, to guide palliative care for this population. In this prospective, descriptive study, we will identify trajectories of symptoms, physical functioning, psychosocial needs, and emotional and spiritual well-being in 200 patients with ESKD who are at a high risk of experiencing acute life-threatening events and mortality within 12 months.

Interventions

None listed

Sponsors

National Institute of Nursing Research (NINR)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 years or older; * receiving either Hemodialysis or Peritoneal dialysis * on dialysis either \< 3 months or ≥ 6 months with a Charlson Comorbidity Index (CCI) score ≥ 5

Exclusion criteria

* Patients who are enrolled in hospice or too sick to participate in questionnaire completion will not be eligible. * Kidney transplant candidates will be excluded because their illness trajectories after transplant are likely to differ.

Design outcomes

Primary

MeasureTime frame
Symptoms, physical functioning, psychosocial needs, spiritual well-being, cognitive functioning12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026